Galena Biopharma, Inc. and Keryx Biopharmaceuticals, Inc. Could Be Big Movers in Healthcare Today

Today's morning movers in the biotech sector.

Jan 17, 2014 at 7:46AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! It's time to check in on the early movers in the biotech sector today.

Galena reversing course?
Shares of Galena Biopharma (NASDAQ:GALE) have soared over the past month, gaining 88%. This sudden rise has been fueled mostly by the acquisition of privately held Mills Pharmaceuticals, an upgrade from Roth Capital, and a licensing deal with Dr. Reddy's Laboratories for the company's lead clinical candidate, NeuVax. Not to mention the market's anticipation of the sales numbers for Galena's newly acquired cancer pain medication, Abstral.

Despite all this good news, Galena shares are dropping in premarket this morning, falling over 11%. This precipitous decline appears to be due to an appearance by Galena's CEO, Dr. Mark Ahn, on Jim Cramer's show Mad Money last night.

During the interview, Cramer questioned Dr. Ahn about the history of failures for drugs similar to NeuVax, saying he was skeptical about the drug's chances for approval.

So, what does this mean? My take is that Galena is building out their commercial pipeline nicely with their recent acquisitions, which should help to soften any blow from a possible NeuVax failure next year. That said, a fair amount of the company's $700 million market cap is tied to NeuVax's potential, so there is a fair amount of risk in Galena shares at these prices. But this isn't exactly news. Galena's long-term value has long been coupled to NeuVax, so you shouldn't hit the panic button over this speed bump.

Keryx receives approval for chronic kidney disease drug in Japan
Keryx Biopharmaceuticals (NASDAQ:KERX) is moving higher this morning after announcing that its orally administrated drug ferric citrate for chronic kidney disease, or CDK, was approved in Japan. According to late-stage clinical trial data, the drug is effective at lowering dangerously high phosphate levels in patients suffering from CDK. In Japan, the drug will be marketed by Japan Tobacco and Torii Pharmaceutical under the brand name Riona.

Is this a big deal? In my view, the answer is both yes and no. What's key going forward are the potential approvals for the drug in the U.S. and Europe. According to statements made by Keryx's management at the J.P. Morgan Healthcare Conference this week, the drug could potentially see approvals in both markets by year's end. As a reminder, the drug is set to be reviewed by the U.S. Food and Drug Administration on June 7 this year.

So while a Japanese approval is a nice upside and even, a potential harbinger of things to come, the real prizes are still on the horizon. The good news is that analysts at Roth Capital, among others, are optimistic about the drug's chances in the U.S. and EU, upping their price targets by no less than an eye-popping 100% from current levels, as a result . With such optimism surrounding Keryx, you might want to keep tabs on this compelling biotech story going forward. 

2 biotech picks to watch this year
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers